Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted

ARDELYX, INC.

2023-Q1 EPS reported -$0.13 revenue$11,369,000

IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.
Net loss $26.8M ($0.13/share) vs $28.1M ($0.21/share) in prior-year period.
Cash and investments $130.4M as of March 31, 2023; raised $51.9M from ATM offering.
XPHOZAH NDA resubmitted to FDA on April 17, 2023 for phosphate control in CKD patients on dialysis.
Licensed TGR5 agonist portfolio to METiS Therapeutics for $750K upfront + up to $243M milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ARDELYX, INC. reported the quarter ended March 31, 2023 results: revenue $11.4 million, net income $26.8 million, EPS $(0.13) per share.

Period: the quarter ended March 31, 2023
Revenue: $11.4 million
Net income: $26.8 million
EPS: $(0.13) per share
Result: reported results

Exact text from the filing

EX-99.1 (EX-99.1) --- Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-015205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.